Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 30, 2025 - Satsuma Pharmaceuticals announced the FDA approval of Atzumi (dihydroergotamine) nasal powder, for the acute treatment of migraine with or without aura in adults.
Download PDF
Return to publications
